ANTIANGIOGENNYE PREPARATY V LEChENII RAKA MOLOChNOY ZhELEZY


如何引用文章

全文:

详细

Рассматривается значение ангиогенеза в прогрессировании и дальнейшем метастазировании опухоли. Подчеркивается, что ангиогенез является привлекательной мишенью для целенаправленной ("таргетной") противоопухолевой терапии. Можно рассчитывать, что при раке молочной железы и других злокачественных опухолях проведение антиангиогенной терапии станет наиболее эффективным видом адъювантного лечения на ранних этапах развития метастазов и до васкуляризации опухоли. Представлены результаты клинических исследований, подтверждающих эффективность бевацизумаба, блокирующего рецепторное связывание VEGF (наиболее мощного стимулятора ангиогенеза), у больных метастатическим раком молочной железы.

全文:

受限制的访问

参考

  1. National Cancer Institute. SEER Cancer Statistics Review. 2003.
  2. WHO web site. Available at: http://www.who.int
  3. Fidler, Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-88.
  4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
  5. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
  6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 ;285:1182-86.
  7. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999;58:17-38.
  8. Guidi A.J, Fischer L, Harris J.R, et al. Micro vessel density and distribution in ductal carcinoma in situ of the breast. J Nati Cancer Inst 1994;86: 614-19.
  9. Guinebretiere J.M, Le Monique G, Gavoille A, et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Nati Cancer mst 1994;86:635-36.
  10. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Nati Cancer mst 1992;84: 1875-87.
  11. Weidner N, Semple J.P, Welch W R, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
  12. Ferrara N, Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
  13. Itakura J, Ishiwata T, Shen B, et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000;85(1):2 7-34.
  14. Liu C.D, Tilch L, Kwan D, et al. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J Surg Res 2002;102(1):31-34.
  15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrin Rev 1997;18(1):4-25.
  16. Takahashi M, Yoshimoto T, Kubo H. Molecular mechanisms of lymphangiogenesis. Int J Hematol 2004;80:29-34.
  17. Obermair A, Kucera E, Mayerhofer K, et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 1997;74:455-58.
  18. Rak J, Yu J.L, Kerbel R.S, et al. What do oncogenic mutations have to do with angiogenesis/ vascular dependence of tumors? Cancer Res 2002;62:1931-34.
  19. Meng S, Tripathy D, Frenkel E.P, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
  20. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787.
  21. Torres Filho I.P, Leunig M, Yuan F, et al. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Nati Acad Sci USA 1994;91:2081 -85.
  22. Aguirre-Ghiso J, Estrada Y, Liu D, et al. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-95.
  23. Naumov G.N, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Nati Cancer mst 2006;98:316-25.
  24. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-12.
  25. Carmeliet P, Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
  26. Relf M, LeJeune S, Scott P.A, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-69.
  27. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
  28. Price D.J, Miralem T, Jiang S, et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001;12:129-35.
  29. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
  30. Ferrara N, Gerber H.P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76.
  31. Eliceiri B.P, Paul R, Schwartzberg P.L, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-24.
  32. Presta L.G, Chen H, O'Conner S.J, et al. Humanization of an anti-Vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and the other disorders. Cancer Res 1997;57:4593-99.
  33. Zon R, Miller K.D, Wang M, et al. A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern Cooperative Oncology Group Trial E2100. Eur J Cancer 2006;4(2 Suppl.):46.
  34. Klencke B.J, et al. Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol 2008;26(Suppl.): abstr. 1036.
  35. Harmey J.H, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280-83.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2009
##common.cookie##